LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017-2018 and 2020-2021 following a WHO Survey.

    Kirichenko, Alina / Kireev, Dmitry / Lapovok, Ilya / Shlykova, Anastasia / Lopatukhin, Alexey / Pokrovskaya, Anastasia / Ladnaya, Natalya / Grigoryan, Trdat / Petrosyan, Arshak / Sarhatyan, Tatevik / Sargsyants, Narina / Hovsepyan, Tamara / Ghazaryan, Hovsep / Hovakimyan, Hermine / Martoyan, Siranush / Pokrovsky, Vadim

    Viruses

    2022  Volume 14, Issue 11

    Abstract: The increased antiretroviral therapy (ART) coverage of patients in the absence of routine genotyping tests and in the context of active labor migration highlight the importance of HIV-1 drug resistance (DR) surveillance in Armenia. We conducted a two- ... ...

    Abstract The increased antiretroviral therapy (ART) coverage of patients in the absence of routine genotyping tests and in the context of active labor migration highlight the importance of HIV-1 drug resistance (DR) surveillance in Armenia. We conducted a two-phase pretreatment DR (PDR) study in 2017-2018 (phase I; 120 patients) and 2020-2021 (phase II; 133 patients) according to the WHO-approved protocol. The analysis of HIV-1 genetic variants showed high degrees of viral diversity, with the predominance of A6. The prevalence of any PDR was 9.2% in phase I and 7.5% in phase II. PDR to protease inhibitors was found only in 0.8% in phase II. PDR to efavirenz and nevirapine was found among 5.0% and 6.7% of patients in phase I, and 6.0% and 6.8% of patients in phase II, respectively. The prevalence of PDR to nucleoside reverse-transcriptase inhibitors decreased from 5.0% in phase I to 0.8% in phase II. In addition, we identified risk factors associated with the emergence of DR-male, MSM, subtype B, and residence in or around the capital of Armenia-and showed the active spread of HIV-1 among MSM in transmission clusters, i.e., harboring DR, which requires the immediate attention of public health policymakers for the prevention of HIV-1 DR spread in the country.
    MeSH term(s) Humans ; Male ; Pregnancy ; Female ; HIV-1/genetics ; Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; Drug Resistance, Viral/genetics ; Prevalence ; Homosexuality, Male ; Armenia/epidemiology ; Sexual and Gender Minorities ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Infections/prevention & control ; HIV Seropositivity ; World Health Organization ; Genotype ; Mutation
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2022-10-22
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v14112320
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006-2022.

    Kirichenko, Alina / Kireev, Dmitry / Lapovok, Ilya / Shlykova, Anastasia / Lopatukhin, Alexey / Pokrovskaya, Anastasia / Bobkova, Marina / Antonova, Anastasiia / Kuznetsova, Anna / Ozhmegova, Ekaterina / Shtrek, Sergey / Sannikov, Aleksej / Zaytseva, Natalia / Peksheva, Olga / Piterskiy, Michael / Semenov, Aleksandr / Turbina, Galina / Filoniuk, Natalia / Shemshura, Andrey /
    Kulagin, Valeriy / Kolpakov, Dmitry / Suladze, Aleksandr / Kotova, Valeriya / Balakhontseva, Lyudmila / Pokrovsky, Vadim / Akimkin, Vasiliy

    Viruses

    2023  Volume 15, Issue 4

    Abstract: In Russia, antiretroviral therapy (ART) coverage has significantly increased, which, in the absence of routine genotyping testing, could lead to an increase in HIV drug resistance (DR). The aim of this study was to investigate the patterns and temporal ... ...

    Abstract In Russia, antiretroviral therapy (ART) coverage has significantly increased, which, in the absence of routine genotyping testing, could lead to an increase in HIV drug resistance (DR). The aim of this study was to investigate the patterns and temporal trends in HIV DR as well as the prevalence of genetic variants in treatment-naïve patients from 2006 to 2022, using data from the Russian database (4481 protease and reverse transcriptase and 844 integrase gene sequences). HIV genetic variants, and DR and DR mutations (DRMs) were determined using the Stanford Database. The analysis showed high viral diversity, with the predominance of A6 (78.4%), which was the most common in all transmission risk groups. The overall prevalence of surveillance DRMs (SDRMs) was 5.4%, and it reached 10.0% in 2022. Most patients harbored NNRTI SDRMs (3.3%). The prevalence of SDRMs was highest in the Ural (7.9%). Male gender and the CRF63_02A6 variant were association factors with SDRMs. The overall prevalence of DR was 12.7% and increased over time, primarily due to NNRTIs. Because baseline HIV genotyping is unavailable in Russia, it is necessary to conduct surveillance of HIV DR due to the increased ART coverage and DR prevalence. Centralized collection and unified analysis of all received genotypes in the national database can help in understanding the patterns and trends in DR to improve treatment protocols and increase the effectiveness of ART. Moreover, using the national database can help identify regions or transmission risk groups with a high prevalence of HIV DR for epidemiological measures to prevent the spread of HIV DR in the country.
    MeSH term(s) Humans ; Male ; HIV-1/genetics ; Anti-HIV Agents/pharmacology ; Anti-HIV Agents/therapeutic use ; Drug Resistance, Viral/genetics ; HIV Infections/drug therapy ; HIV Infections/epidemiology ; HIV Seropositivity ; Mutation ; Genotype ; Prevalence ; Russia/epidemiology
    Chemical Substances Anti-HIV Agents
    Language English
    Publishing date 2023-04-18
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2516098-9
    ISSN 1999-4915 ; 1999-4915
    ISSN (online) 1999-4915
    ISSN 1999-4915
    DOI 10.3390/v15040991
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top